Less is best? The impact of urokinase as the first line management of empyema thoracis.
To assess the impact of intrapleural urokinase and small tube thoracostomy on the management of childhood empyema thoracis. The study population included 38 children presenting consecutively to a regional surgical unit with empyema thoracis from January 2001 to December 2003. Children with malignancy, immunodeficiency and complex intercurrent illness were excluded. Primary outcome variables were the need for second intervention and duration of stay, with other variables including duration of antibiotics, serial CRP and amelioration of pyrexia. Interventions were: tube thoracostomy (16-20 Fr) alone (n=2), tube thoracostomy (6-10 Fr)+urokinase (n=17), thoracoscopy (tube: 20-24 Fr) (n=9), thoracotomy (tube: 16-24 Fr) (n=10). There were no differences in age, weight or length of prodromal symptoms, between treatment groups. There were no differences in primary outcome variables, although no child undergoing thoracotomy required further intervention. The duration of intravenous antibiotics was similar in all groups. Amelioration of pyrexia was more rapid in children undergoing thoracotomy. There were no differences seen with regard to decline in CRP level. Small tube thoracostomy and intrapleural urokinase had a similar outcome to more invasive therapies such as thoracotomy or thoracoscopy thereby supporting the evidence base for urokinase and tube drainage as first line intervention.
Khalil
B A
BA
Department of Paediatric Surgery, The Royal Liverpool Children's Hospital (Alder Hey), Eaton Road, The University of Liverpool, L12 2AP, UK. Kba_bas@hotmail.co.uk
Corbett
P A
PA
Jones
M O
MO
Baillie
C T
CT
Southern
Kevin
K
Losty
P D
PD
Kenny
S E
SE
D002097:C-Reactive Protein / Q000032:analysis; D002675:Child, Preschool; D016724:Empyema, Pleural / Q000188:drug therapy* / Q000628:therapy; D005260:Female; D006801:Humans; D007223:Infant; D007902:Length of Stay; D008297:Male; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D013907:Thoracostomy; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D012597:Sclerosing Solutions; D002097:C-Reactive Protein; D014568:Urokinase-Type Plasminogen Activator